



Multiple Resistance in Clinical Isolates of *Escherichia coli* and Plasmid-mediated Quinolone Resistance Genes

Ugo U. Anayo^a, Nna E. Okechukwu^b,
Onyemelukwe F. Ngozi^a, Samson O. Aisida^{c*}
and Canice C. Anyachukwu^d

^a Department of Medical Laboratory Science, University of Nigeria, Enugu Campus, Enugu, Nigeria.

^b Safety Molecular Pathology Laboratory, Molecular Pathology Institute, Enugu State, Nigeria.

^c Department of Physics and Astronomy, University of Nigeria, Nsukka 41000, Nigeria.

^d Department of Medical rehabilitation, University of Nigeria, Enugu Campus, Enugu, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. Author UUA helped in conceptualization, did data curation, performed methodology and wrote original draft of the manuscript. Author NEO helped in Data curation, Investigated the study and edited the manuscript. Author OFN helped in data Visualization and Reviewed the manuscript. Author SOA drafted and Edited original data. Author CCA edited the final manuscript. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/ARRB/2023/v38i230568

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/95523>

Original Research Article

Received: 11/11/2022

Accepted: 14/01/2023

Published: 08/03/2023

ABSTRACT

Quinolone antibiotics have been commonly used to treat cases of multiple antibiotic resistance. Unfortunately, quinolone antibiotics have so much been resisted by infectious bacterial agents. This study aimed to evaluate the susceptibility of some clinical isolates of *E. coli* to some commonly used quinolone antibiotics and the determination of the plasmid-encoded quinolone resistance genes. Our results showed the plasmid quinolone-resistance genes in the following prevalence: qnr S (71.4 %); qnr B (15.4 %); qnr S and B (12.1 %); aac (6) lb-cr (4 %); Efflux genes: oqxA (7.7

*Corresponding author: E-mail: samson.aisida@unn.edu.ng;

); oqxB (25.3 %); qepA (12.1 %); oqxA and oqxB (5.5 %). We conclude that there is a high frequency of Plasmid-mediated quinolone resistance genes in *Escherichia coli* isolates from clinical samples in South-Eastern Nigeria. These could be responsible for the high incidence of quinolone resistance reported in Enugu. There is a need for whole-genome sequencing to map out all resistance genes.

Keywords: *Escherichia coli*; quinolone antibiotics; plasmid; antibiotics; quinolone genes

1. INTRODUCTION

Resistance of infectious microorganisms have been a great concern to all globally [1]. Antibiotic resistance occurs when any drug meant to hinder bacterial growth or kill the bacteria fail to exhibit any lethal action on the microorganism or hinder its growth, such that the bacteria grow and multiply in the presence of that drug [2]. The first serious consequence of antibiotic resistance in medical therapy was the gross dissemination of strains of *Staphylococcus aureus*, which were resistant to penicillin, described as penicillin-resistant *Staphylococcus aureus* [3] Currently, Multi-Drug Resistance (MDR) has become major public health concern all over the world [1,4]. Among the present-day superbugs are the multidrug-resistant *Escherichia coli* (*E. coli*).

Quinolones are a family of synthetic broad-spectrum antibiotics, which are drugs of choice commonly used to treat bacterial infections worldwide [5,6] Resistance to the first-generation quinolones led to the manufacture and introduction of stronger members of the quinolones, otherwise known as the fluoroquinolones [7,8]

Many studies have attributed the frequency of quinolone resistance to carriage of plasmid, which has been found to contain genes for quinolone resistance [9,10]. The Plasmid-mediated quinolone resistance includes the qnr genes, majorly qnrA, qnr B and qnr S; the aminoglycoside acetyltransferase gene (aac-6'-Ib-cr) and specific efflux pumps' genes, qepA, oqxA and OqxB [11,12]. Owing to the high resistance of *E. coli* to the quinolones, there is an urgent need to find out how *Escherichia coli* is resisting these drugs. This will enable further research for modifications on the drugs.

In this work, clinical isolates of *E. coli* were screened for quinolone resistance, after which the plasmid-mediated quinolone resistance was investigated. The resistance genes mediated by plasmids may be of epidemiologic importance in the rapid spread of antibiotic resistance even to

bacteria of other species and consequently, elevate antibiotic resistance.

2. MATERIALS AND METHODS

2.1 Study Population and Sampling Method

A total of 274 isolates of presumptively identified *E. coli*, were collected from 13 Medical Laboratories/Diagnostic Centers in Enugu State and from 10 different clinical samples. The samples include pus aspirates, catheter tip, ear swab, Endocervical swab (ECS), High Vaginal Swab (HVS), semen, stool from infants, throat Swab, urine and wound swab. A convenience method of non-probability sampling was employed.

2.2 Identification and Characterization of the *E. coli* Isolates

A loopful of the *E. coli* isolate from Brain Heart Infusion agar storage or directly from MacConkey or Blood agar medium was aseptically picked and streaked on Chromagar to enable the growth of pure colonies. This was incubated at 37 °C for 24 h. The colonies of *E. coli* would appear dark-blue while the non-*E. coli* (other coliforms) would appear colorless/ white. A pure colony identifiable as *E. coli* was streaked on Mueller-Hinton agar MHA (Oxoid) plate for luxuriant colonies. Further biochemical characterization, using Triple Sugar Iron agar (TSI); IMVC (I = indole; M= Methyl Red; V = Voges Proskauer; C = citrate) and Urease were carried out.

2.2.1 Triple sugar tests

Triple Sugar Iron medium is a differential medium that can distinguish between a number of Gram negative enteric bacteria based on their physiological ability to metabolize lactose and/or sucrose; produce acid and /or gas during fermentation and generate H₂S. The medium contained 1.0% each of sucrose and lactose and 0.1% glucose. If only glucose was fermented, acid produced in the butt would turn it yellow, but insufficient acid products would form to affect the

methyl red in the slant. If either sucrose or lactose were fermented, sufficient fermentation products would be formed to turn both the butt and the slant yellow. If gas was formed during the fermentation, it would show in the butt either as bubbles or as cracking of the agar. If no fermentation occurred (as for an obligate aerobe), the slant and butt would remain red. The medium also contained ferrous sulfate. If the bacterium formed H₂S, this chemical would react with the iron to form ferrous sulfide, which would be seen as a black precipitate in the butt (a black butt). The Triple sugar iron agar (oxid) powder was prepared according to manufacturer's instruction It was then allowed to set in slants 1 inch deep. A single colony from the Muller Hilton agar (MHA) was streaked on the slant and stabbed on the butt. Incubation of the slant was done at 42°C for 18 hours for change of colour and possible result.

2.2.2 Indole test

This tests the ability of an organism to degrade tryptophan based on the possession of tryptophanase enzyme, producing indole, a by-product. Indole is detected using Kovac's reagent which contains p-dimethylaminobenzaldehyde (DMAB). Positive test is indicated by red colour in the form of ring in the medium. The production of Indole was tested using SIM (Sugar, Indole and Motility) medium agar, (oxid) product. The SIM medium was prepared according to company's specification. Once cool, the pure colony from MHA was inoculated once, by inserting a straight wire to about one third of the depth of the medium. The culture was incubated at 42°C for 18 hours. To test for indole production a drop of Kovac's reagent was put in the tube. A positive result was indicated by appearance of a red ring in the medium. No change in colour was observed for a negative result.

2.2.3 Methyl –Red (MR)- Voges Proskauer (VP) test

Methyl red tests the ability of bacteria to metabolize glucose with production of mixed acid products (lactic, acetic, formic and succinic). This would result to a decrease in the pH of the medium and a positive MR test. The pH must drop to 4.4 or less for the MR indicator to take on its acidic red color. Voges Proskauer tests the ability of bacteria to metabolize glucose with production of acetyl methyl carbine acetoin which is an intermediate product to butylene glycol. This intermediate neutral product is then

assayed. In the presence of oxygen and 40 % potassium hydroxide, acetoin is converted to the diacetyl form, which results in a red color in the presence of alpha-naphthol.

The methyl red (MR) and Voges-Proskauer (VP) broth, containing glucose and peptone was prepared and inoculated with a pure colony and incubated at 37°C for 24 hours after which the MR-VP broth was split into two tubes. One tube was used for the MR test; and the other for the VP test. About 5 drops of the methyl red indicator was added to the first tube. Barrit's reagents, 3ml of solution A containing naphtholin and 1 ml of solution B containing 40 % potassium hydroxide solution were added to the second tube. A positive result was indicated by the appearance of red colour in the medium, while a negative result showed no change of colour.

2.2.4 Citrate test

Principle: The citrate test screens a bacterial isolate for the ability to utilize citrate as its carbon and energy source. A positive diagnostic test rests on the generation of alkaline by-products of citrate metabolism. The subsequent increase in the pH of the medium is demonstrated by the colour change of a pH indicator. Citrate agar powder was prepared according to manufacturer's instruction and used in slants. Pure colony from MHA was inoculated on slant and stabbed to the butt. The slant was then incubated at 37 °C for 24hours. Positive test was indicated by a change in colour of the medium from green to blue; whereas no change in colour indicated negative result.

2.2.5 Urease tests

This tests the ability of bacteria to split urea into ammonia (NH₃), CO₂ and water (H₂O), based on the possession of urease. Ammonia reacts in solution to form an alkaline compound, ammonium carbonate, which results in an increased pH of the medium and a color change in the indicator to pink red.

Urea Agar Base (Oxoid) was prepared according to manufacturer's instruction. One ampule of 40% sterile urea solution was added aseptically and mixed well. 10 ml was distributed into sterile tubes and allowed to set in the slope position. Pure colony from MHA was stab inoculated in the Urease agar, covered with cotton wool and incubated for 24 hours. Positive test was indicated by change in colour from yellow to pink colour.

2.3 Antimicrobial Sensitivity Tests

Confirmed *E. coli* were confirmed using *E. coli* Chromagar and the biochemical tests and then tested for quinolone resistance using the disk diffusion method for carrying out the cultivation and sensitivity test of the *Enterobacteriaceae* as shown in Fig. 1. The standard guidelines employed were those of the Clinical and Laboratory Standards Institute (2019), and that of the British Society for Antimicrobial Chemotherapy (BSAC), as highlighted by Howe and Andrews [13]. The bacterial colony was inoculated in 5ml sterile normal saline and adjusted to a 0.5 McFarland Standard. A sterile cotton wool swab was dipped in the prepared bacterial suspension and used to streak the surface of Mueller Hinton Agar plates, ensuring the entire smooth uniform coverage of the plates. Filter paper disks impregnated with known concentrations of the antibiotics: *Ciprofloxacin* (10 ug), *Ofloxacin* (30 ug), *Pefloxacin* (10 ug), *Sparfloxacin* (10 ug), *Moxifloxacin* (5 ug) and *Levofloxacin* (20ug) obtained commercially (Maxi-care) were used and deposited on the agar plate surface. The plates were incubated at 37 °C for 24 h. The result was interpreted using BSAC standard for Quinolone antibiotic breakpoint for *Enterobacteriaceae* using zone of inhibition [13].

2.4 Extraction of Plasmid DNA

Extraction of Plasmid DNA from the isolates was done using Zymo Research Plasmid Miniprep *Classic* kit (ZR, USA). The plasmid wash buffer was constituted by adding ethanol (100%) to the supplied buffer. 0.5 ml of bacterial culture (bacterial colony emulsified in Tris EDTA buffer pH 8.0) stored in a clear 1.5 ml tube was centrifuged at full speed for 20 seconds in a micro-centrifuge. 200 µl of P1Buffer was added to the tube and the pellet was re-suspended completely (by vortexing). Then 200 µl of P2 Buffer was added and the contents mixed by inverting the tube 4 times, without vortexing, and then incubated for 2 minutes to ensure complete lysis of the cells. 400 µl of P3 Buffer was added and contents mixed gently but thoroughly, without vortexing. The sample turned yellow, indicating complete neutralization. The lysate was then allowed to incubate at room temperature for 2 mins and then centrifuged for 2 min at 15,000 rpm.

3. RESULTS

3.1 *Escherichia coli* Isolates

Table 1 shows the sample types and the corresponding numbers of confirmed *E. coli* isolates. A total of 274 suspected *E. coli* isolates were collected from various medical laboratories. The analysis of these isolates indicated that 138 (50.4 %) were actually *E. coli* isolates, while 136 (49.6 %) belonged to other *Enterobacteriaceae* groups. Urine specimens gave the highest number of *E. coli* 102 (37.2 %).

3.2 Susceptibility Test Result of the *E. coli* Isolates to Quinolone Antibiotics

Great majority of the *E. coli* isolates showed resistance to ciprofloxacin 88 (96.7 %); Ofloxacin 91 (100 %); Pefloxacin 84 (92.3 %); sparfloxacin 85 (93.4 %) and moxifloxacin 90 (98.9 %) (Table 2).

3.3 Plasmid Mediated Resistance Gene

3.3.1 *qnr* genes

qnr S genes were found the most prevalent quinolone (*qnr*) gene in the clinically isolated *E. coli*, with a prevalence rate of 71.4 %. *qnr* B was present in fifteen of the isolates at the rate of 15.4 %. *qnr* A was not detected in any of the isolates. Eleven (12.1 %) of the isolates showed both *qnr*S and *qnr* B. Table 3 shows the frequency of plasmid-mediated quinolone (*qnrA*, *qnrB*, *qnrS*) genes and Fig. 2a shows the *qnr* genes on agar gel. *oqx*B of the Efflux pump gene recorded the highest prevalence (25.3 %), followed by *qepA* (12.1 %), and then, *oqx*A (7.7 %) (Table 3).

3.3.2 The Aminoglycoside Acetyltransferase Gene

The Aminoglycoside acetyltransferase gene was seen only in four isolates (4%) (Table 3). Fig. 2b shows the *aac* (6) *lb-cr*, and the three efflux genes, *oqx*A, *oqx*B and *qep*A. The *aac*-(6) *lb-cr* is 482 bp and lies close to the 500 bp of the ladder; *oqx*A is 392 bp and is located close to the fourth bar (400 bp) of the ladder; *oqx*B is 512 bp and is found above the 500 bp of the ladder, while *qep*A is 199 bp and lies close to 200 bp of the ladder.



Fig. 1. Sensitivity pattern of the *E. coli* isolates

Table 1. Clinical sources of samples for isolation of *Escherichia coli*

| Sample type | Presumed <i>E. coli</i> | Confirmed <i>E. coli</i> | Percentage |
|--------------|-------------------------|--------------------------|------------|
| Pus Aspirate | 1 | 1 | 0.4 |
| Catheter tip | 2 | 1 | 0.4 |
| Ear swab | 1 | 0 | 0 |
| ECS | 4 | 0 | 0 |
| HVS | 11 | 5 | 1.8 |
| Semen | 5 | 1 | 0.4 |
| Stool | 24 | 15 | 5.5 |
| Throat Swab | 1 | 0 | 0 |
| Urine | 176 | 102 | 37.2 |
| Wound Swab | 49 | 13 | 4.7 |
| Total | 274 | 138 | 50.4 |

ECS is an Endocervical swab, *HVS* is a high vaginal swab. About 50.4 % of pre-diagnosed *E. coli* from participating laboratories were confirmed *E. coli* using the *E. coli* Chromagar

3.3.3 Clinical *E. coli* isolates and PMQR gene carriage

Given the total of 91 *E. coli* isolates subjected to Plasmid quinolone-resistant genes, 68 (74.7 %) were positive for *qnr* genes while 23 (25.3 %) were negative for *qnr* genes; 36(39.6 %) were positive for the *Efflux* pump genes, while 54 (59.3 %) were negative; only 4 (4.4 %) were positive for the *aac (6') Ib-cr* while the great majority 87 (95.6 %) were negative as presented in Table 4.

3.3.4 Plasmid gene and the antibiotic profiles of the *E. coli* isolates

Tables 5 and 6 showed the plasmid gene profile of the *E. coli* Isolates and their frequencies. The profile with the highest frequency is *Qnr* alone 36 (39.6 %), followed by *QNR /Efflux*, 28 (30.8 %), and then *efflux* alone 5(5.5 %). A total of 18(19.8 %) of the population were found to possess none of the genes. Going down the analysis into the *PMQR* gene profile in Table 6, *Qnr S* occurring alone has the highest-profile (30.8 %), followed by *QnrS/OqxB (QNR /Efflux)*,12.1 %

and then followed by *Qnr S/ QepA* (also *QNR /Efflux*), 8.8 % as detected in section 2.5.


3.3.5 Quinolone drugs and *E. coli* resistance: Plasmid gene predominance and frequency

Qnr S is shown to be the leading gene in all the Resisted quinolones. There is also a low frequency of *Qnr S* coexisting with *Qnr B* in all the drugs. The *efflux* pump gene, *OqxB* was the most frequent of the *efflux* pump genes and was found to occur alone or in combination with the other *efflux* or *Qnr* genes. In almost all the drugs (except in Levofloxacin that was least resisted), all the *PMQR* genes, *Qnr*, *aac (6') Ib-cr*, and *efflux* pumps were all fully represented, alone in combination with others as shown in Table 7.


Table 8(a) and (b) show the antibiotic profile of the clinical *E. coli* isolates and the summary, respectively. The six and the five-antibiotic resistance profiles had the highest frequency of 27 (29.7 %) and 42 (46.2 %), respectively, with all the different genes elaborated.

Table 2. Susceptibility of *E. coli* isolates to quinolone antibiotics

| Antibiotic | Sensitive | Intermediate | Resistant | Percentage of the Resistant Isolates |
|---------------|--------------------|--------------|--------------------|--------------------------------------|
| Ciprofloxacin | 2 (≥ 20 mm) | 1 (17-19mm) | 88 (≤ 16 mm) | 96.7 |
| Ofloxacin | 0 (≥ 29 mm) | 0 (26-28mm) | 91 (≤ 25 mm) | 100.0 |
| Pefloxacin | 4 (≥ 20 mm) | 3 (17-19mm) | 84 (≤ 16 mm) | 92.3 |
| Pefloxacin | 6 (≥ 20 mm) | 0 (17-19mm) | 85 (≤ 16 mm) | 93.4 |
| Moxifloxacin | 0 (≥ 20 mm) | 1 (17-19mm) | 90 (≤ 16 mm) | 98.9 |
| Levofloxacin | 33 (≥ 17 mm) | 16 (14-16mm) | 41 (≤ 13 mm) | 45.1 |



(a)



(b)

Fig. 2. (a) qnr genes (b) Aminoglycosyl acetyltransferase and efflux genes

Table 3. Frequency of plasmid-mediated quinolone resistance genes in *E. coli*

| Type of gene | Specific gene | Positive Cases | Percentage |
|----------------|---------------|----------------|------------|
| qnr | qnrS | 65 | 71.4 |
| | qnrB | 14 | 15.4 |
| | qnrA | 0 | |
| | qnrS & B | 11 | 12.1 |
| amg | aac (6) lb-cr | 4 | 4.4 |
| Efflux | oqxA | 7 | 7.7 |
| | oqxB | 23 | 25.3 |
| | qeqA | 11 | 12.1 |
| | oqxA & oqxB | 5 | 5.5 |
| No Gene | | 18 | |

Table 4. No of the *E coli* isolates positive and negative for the PMQR genes (N=91)

| PMQR Gene | No positive | % age | No Negative | % age |
|------------------------------|-------------|-------|-------------|-------|
| Qnr | 68 | 74.4 | 23 | 25.3 |
| Efflux | 36 | 39.6 | 54 | 59.3 |
| Aac(6') ib-cr | 4 | 4.4 | 87 | 95.6 |
| Total Positive for PMQR Gene | 73 | 80.2 | | 93.4 |
| Total negative for PMQR Gene | | | 18 | 19.8 |

Table 5. Frequency table of the plasmid gene profile of the *E. coli* isolates

| Gene profile | Frequency | Percentage frequency |
|------------------|-----------|----------------------|
| QNR/ EFFLUX/ AMG | 1 | 1.1 |
| QNR / EFFLUX | 28 | 30.8 |
| QNR/ AMG/ | 1 | 1.1 |
| EFFLUX/ AMG | 1 | 1.1 |
| EFFLUX/ | 5 | 5.5 |
| QNR / | 36 | 39.6 |
| AMG/ | 1 | 1.1 |
| None Present | 18 | 19.8 |

Table 6. Quinolone resistance gene profile of the *E. coli* isolates

| Gene profile | Frequency | Percentage frequency |
|-------------------|-----------|----------------------|
| QNR S/QNRB/OqXB | 2 | 2.2 |
| QNR S/QNRB/OqXA | 0 | 0.0 |
| QNR S/QNRB/qepA | 2 | 2.2 |
| QNR S/QNRB/AA | 1 | 1.1 |
| QNR B/OqxB | 1 | 1.1 |
| QNR B/OqxA | 0 | 0.0 |
| QNR B /qEpA | 0 | 0.0 |
| QNR S/OqxB | 11 | 12.1 |
| QNR S/ qEpA | 8 | 8.8 |
| QNR S/ qEpA/AA | 1 | 1.1 |
| QNR S/OqxA | 1 | 1.1 |
| QNR S/OqxA/AA | 1 | 1.1 |
| QNRS/OqxA/OqxB | 3 | 3.3 |
| QNR B/OqxA/OqxB | 0 | 0.0 |
| QNRS/OqxA/OqxB/AA | 1 | 1.1 |
| QNR S/QNRB | 6 | 6.6 |
| OqxA/OqxB | 1 | 1.1 |

| Gene profile | Frequency | Percentage frequency |
|--------------|-----------|----------------------|
| QNR S/ | 28 | 30.8 |
| QNR B/ | 2 | 2.2 |
| OqxA/ | 0 | 0.0 |
| OqxB/ | 4 | 4.4 |
| qEpA/ | 0 | 0.0 |
| AA/ | 0 | 0.0 |
| None / | 18 | 19.8 |
| Total | 91 | 100 |

Table 7. Frequency of the plasmid quinolone genes in the quinolone drugs

| Quinolone | Aac (6') Ib-cr + Efflux Genes | | | | | | | | | | | |
|------------|-------------------------------|-------|---------|----|--------------------|------|------|------|-----------|-------------|----------------|----------|
| | Qnr S | Qnr B | QNR B+S | AA | Efflux Gene Absent | OqxA | OqxB | QepA | AA + OqxA | OqxA + OqxB | AA+ OqxA +OqxB | AA+ QepA |
| cip (n=88) | 64 | 14 | 11 | 4 | 52 | 6 | 22 | 11 | 1 | 3 | 1 | 1 |
| oflo (91) | 65 | 14 | 11 | 4 | 51 | 7 | 23 | 11 | 1 | 4 | 1 | 1 |
| Pef (n=84) | 61 | 12 | 10 | 4 | 47 | 7 | 23 | 11 | 1 | 4 | 1 | 1 |
| spa(n=85) | 61 | 12 | 10 | 4 | 49 | 6 | 22 | 11 | 1 | 3 | 1 | 1 |
| Moxi(n=90) | 53 | 13 | 10 | 4 | 52 | 6 | 22 | 11 | 1 | 4 | 1 | 1 |
| levo(n=41) | 30 | 6 | 5 | 1 | 22 | 3 | 14 | 4 | 0 | 1 | 1 | 0 |

Cip = ciprofloxacin; Oflo= Ofloxacin; pef= pefloxacin; Spa= Spafloxacin; Moxi = moxifloxacin; Levo= levofloxacin; AA=aac (6') Ib-cr (aminoglycosyl acetyltransferase gene)

Table 8(a). Antibiotic profile of *E. coli* isolates and their plasmid genes

| Antibiotic Profile | Total No of Isolate | Qnr gene(s) Present | Efflux gene(s) Present | AMG gene Present |
|--------------------------------|---------------------|---------------------|------------------------|------------------|
| Cip/Oflo /pef / Spa Moxi/ Levo | 27 | 19 | 8 | 1 |
| Cip/ Oflo/ pef /Spa/ Moxi | 41 | 31 | 22 | 2 |
| S/N | 1 | 1 | 0 | 0 |
| Cip/ pef /Spa/ Moxi | 1 | 1 | 1 | 0 |
| Cip/ Oflo/ Spa/ Moxi | 2 | 2 | 0 | 1 |
| Cip/ Oflo/ pef// Spa | 8 | 7 | 3 | 0 |
| Cip Oflo/ pef | 1 | 1 | 0 | 0 |
| Cip/ pef/ Moxi | 1 | 0 | 0 | 0 |
| Cip/ Spa/ Moxi | 1 | 0 | 0 | 0 |
| Oflo/ Moxi/ levo | 1 | 1 | 1 | 0 |
| Pef/ Spa/ moxi | 1 | 1 | 1 | 0 |
| Spa/ Moxi | 1 | 0 | 0 | 0 |
| Cip/ moxi | 1 | 1 | 0 | 0 |
| Cip | 4 | 4 | 0 | 0 |

Cip = ciprofloxacin; Oflo= Ofloxacin; pef= pefloxacin; Spa= Spafloxacin; Moxi = moxifloxacin; Levo= levofloxacin; ATCC= American Typed; EC=*E. coli*

Table 8(b). Antibiotic profile of the resistant *E. coli* isolates and their plasmid genes

| Number of Antibiotics Resistant To | Number of Strains Showing Pattern | Qnr Gene Present | Efflux Gene Present | AMG Gene Present |
|------------------------------------|-----------------------------------|------------------|---------------------|------------------|
| One Antibiotic (Cip Only) | 4 | 4 | 0 | 0 |
| Two Antibiotics | 3 | 1 | 0 | 0 |
| Three Antibiotics | 5 | 3 | 2 | 0 |
| Four Antibiotics | 11 | 10 | 4 | 1 |
| Five Antibiotics | 42 | 32 | 22 | 2 |
| Six Antibiotics | 27 | 19 | 8 | 1 |

4. DISCUSSION

The results of the susceptibility testing gives a picture of quinolone resistance in the study area. Five of the 6 quinolone drugs were resisted by the greater majority (>90 %) of the *E. coli* isolates.

The frequency of the PMQR genes 73(80.2 %) obtained in this study is much higher than what was found among *E. coli* in Lome, Togo, the frequency of 67.03 % was reported by Salah *et al.* (2019) [14]. Much lower frequencies were obtained in many other places; in Mexico, it was reported in 32.1 %; [15] in the United Kingdom (UK) in 35.2 % [16]. In China in 43.6 %, [17] while in Niger, it was reported in 44.4 % [18]. In the Republic of Korea, the frequency was even lower, 5 % [19]. Similarly, the frequency of the *qnr* genes obtained here varied from what was reported in the other countries. In Mexico, *qnr A* was obtained in clinical isolates of *E coli* in 22.7 %, *qnr B* in 20.9 % and *qnr S* in 6.4 %. In Iran, Firoozeh *et al.*, (2014) obtained 22.2 % of *qnr A* and 14.3 % of *qnr B* from 63 ciprofloxacin-resistant isolates. While similar results of low *qnr A* and *B* were said to have been obtained in Jamaica, UK and Spain; in Japan, a lower frequency of 6.5 % was obtained of *qnr A*, while *qnr S* and *B* were not found [20]. This is a clear contradiction of the current study where *qnr S* and *qnr B* were prevalent and *qnr A* not detected. In Korea, Pallecchi *et al.* (2009) [21] found *qnr B* dominant while *qnr A* was not found. *Qnr S* and *qnr B* as found out in this study, often occurred together in the same isolates with a prevalence of 12 %. The prevalence of *aac (6) lb-cr (4 %)* found in our study is quite low compared to the prevalence of 34.5 % found in the UK by Ciesielczuk *et al.* (2013) and 18 % detected in Southern Nigeria among species of Gram-negative bacteria. However, their presence indicates their availability in our society and their importance in reducing the activity of Ciprofloxacin by N-acetylation at the amino nitrogen on its piperazine substituent [22].

The frequency of the efflux pump genes obtained in this study, 41(18.55 %), is very similar to the percentage frequency of 18.7 % obtained by Ogbolu *et al.*, (2016) [23]. in Southern Nigeria. However, the frequency of *OqxB* and *QepA* is by far higher than what Ciesielczuk *et al* (2013) [16] obtained in the UK. By implication, these genes contribute to the flushing out of the quinolone antibiotics from the cell membrane of the

organism, thereby contributing to the high resistance of the *fluoroquinolones*.

5. CONCLUSION

We report a very high frequency of the Plasmid-mediated quinolone resistance genes in multi-resistant clinical isolates of *Escherichia coli*. *Qnr S* is the leading gene, while *Qnr A* was not detected. The plasmid genes, therefore, contribute to the high quinolone resistance being recorded in our society since more of the genes were detected in those isolates that resisted five and six of the quinolone drugs. The fact that these genes are carried on the Plasmid may facilitate their easy spread to other bacterial species. Whole-genome sequencing will be required to expose the molecular mechanisms of quinolone antibiotic resistance, which will enable better interventions in antimicrobial resistance.

ACKNOWLEDGEMENT

We express our gratitude to Ngozi Attamah and Chinenye, who are staff of the Safety Molecular Pathology Laboratory Enugu, for their great support and assistance.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: A global multifaceted phenomenon. In *Pathogens and Global Health*. 2015;109:309-18. DOI: 10.1179/2047773215Y.0000000030
2. Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A Review on antibiotic resistance: Alarm bells are ringing. *Cureus*. 2017;9:e1403. DOI: 10.7759/cureus.1403
3. WHO, "Antimicrobial resistance. Global report on surveillance." World Health Organization; 2014. [Online]. Available: <https://doi.org/10.1007/s13312-014-0374-3>.
4. Penders J, Stobberingh EE, Savelkoul PHM, Wolfs PFG. The human microbiome as a reservoir of antimicrobial resistance. In *Frontiers in Microbiology*; 2013. Available: <https://doi.org/10.3389/fmicb.2013.00087>.

5. Etienne M, Lefebvre E, Frebourg N, Hamel H, Pestel-Caron M, Caron F, et al. Antibiotic treatment of acute uncomplicated cystitis based on rapid urine test and local epidemiology: Lessons from a primary care series. *BMC Infect Dis.* 2014;14:137. DOI: 10.1186/1471-2334-14-137
6. Martín-Gutiérrez G, Rodríguez-Martínez JM, Pascual Á, Rodríguez-Beltrán J, Blázquez J. Plasmidic qnr genes confer clinical resistance to ciprofloxacin under urinary tract physiological conditions. *Antimicrobial Agents and Chemotherapy.* 2017;61:e02615-16. Available: <https://doi.org/10.1128/AAC.02615-16>
7. Pham TDM, Ziora ZM, Blaskovich MAT. MedChemComm Quinolone antibiotics. *Med. Chem. Commun.* 2019;10:1719–1739. Available: <https://doi.org/10.1039/C9MD00120D>
8. Sárközy G. Quinolones: A class of antimicrobial agents. *Veterinarni Medicina.* 2001;46(9-10):257–274.
9. Tarchouna M, Ferjani A, Marzouk M, Guedda I Boukadida J. Prevalence of plasmid-mediated quinolone resistance determinants among clinical isolates of *Escherichia coli* in a Tunisian hospital. *International Journal of Current Microbiology and Applied Sciences.* 2015; 4:195–206. DOI: 10.4236/aim.2021.1110041
10. Todorović D, Velhner M, Grego E, Vidanović D, Milanov D, Krnjaić D, Kehrenberg C. Molecular characterization of multidrug-resistant *Escherichia coli* isolates from bovine clinical mastitis and pigs in the Vojvodina Province, Serbia. *Microbial Drug Resistance.* 2017;24:95–103. DOI: 10.1089/mdr.2017.0016
11. Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual Á. Plasmid-mediated quinolone resistance: An update. *Journal of Infection and Chemotherapy.* 2011;17:149–182. DOI: 10.1007/s10156-010-0120-2.
12. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. *Biochemistry.* 2014;53:1565–1574. DOI: 10.1021/bi5000564
13. Howe RA, Andrews JM. BSAC standardized disc susceptibility testing method (version 11). *Journal of Antimicrobial Chemotherapy.* 2012;67: 2783–2784. DOI: 10.1093/jac/dks391
14. Salah FD, Soubeiga ST, Ouattara AK, Sadjji AY, Metuor-Dabire A, Obiri-Yeboah D, Banla-Kere A, Karou S, Simpore J. Distribution of quinolone resistance gene (qnr) in ESBL-producing *Escherichia coli* and *Klebsiella spp.* in Lomé, Togo. *Antimicrobial Resistance and Infection Control.* 2019; 8: 1-8. DOI: <https://doi.org/10.1186/s13756-019-0552-0>.
15. Ramírez-Castillo F Y, Moreno-Flores A C, Avelar-González F J, Márquez-Díaz F, Harel J, Guerrero-Barrera A L, An evaluation of multidrug-resistant *Escherichia coli* isolates in urinary tract infections from Aguascalientes, Mexico: Cross-sectional study. *Annals of Clinical Microbiology and Antimicrobials.* 2018;17:34. DOI: 10.1186/s12941-018-0286-5.
16. Ciesielczuk H, Hornsey M, Choi V, Woodford N, Wareham DW. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. *Journal of Medical Microbiology.* 2013;62:1823–1827. DOI: 10.1099/jmm.0.064428-0
17. Yang T, Zeng Z, Rao L, Chen X, He D, Lv L, Wang J, Zeng L, Feng M, Liu J H. The association between occurrence of plasmid-mediated quinolone resistance and ciprofloxacin resistance in *Escherichia coli* isolates of different origins. *Veterinary Microbiology.* 2014;170:89-96. Available: <https://doi.org/10.1016/j.vetmic.2014.01.019>
18. Moumoni A, et al. Quinolone Resistance (qnr) genes in fecal carriage of extended Spectrum beta-lactamases producing Enterobacteria isolated from children in Niger. *Current Research in Microbiology and Biotechnology.* 2017;5:953–957.
19. Hong BK, Chi HP, Chung JK, Kim EC, Jacoby GA, Hooper DC. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. *Antimicrobial Agents and Chemotherapy.* 2009;53:639–645. DOI: 10.1128/AAC.01051-08
20. Firoozeh F, Zibaei M, Soleimani-Asl Y. Detection of plasmid-mediated qnr genes among the quinolone-resistant *Escherichia*

- coli* isolates in Iran. Journal of Infection in Developing Countries. 2014;8:818–822.
DOI: 10.3855/jidc.3746
21. Pallecchi L, Riccobono E, Mantella A, Bartalesi F, Sennati S, Gamboa H, et al. High prevalence of qnr genes in commensal enterobacteria from healthy children in Peru and Bolivia. Antimicrobial Agents and Chemotherapy. 2009;56:26
DOI: 10.1128/AAC.01722-08
22. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Chi HP et al. Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nature Medicine. 2006;12:83–88.
Available: <https://doi.org/10.1038/nm1347>.
23. Ogbolu DO, Alli AO, Anorue MC, Daini OA, Oluwadun A. Distribution of plasmid-mediated quinolone resistance in Gram negative bacteria from a tertiary hospital in Nigeria. Indian Journal of Pathology and Microbiology. 2016;9:322–3.
DOI: 10.4103/0377-4929.188108.

© 2023 Anayo et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/95523>